Forbes March 4, 2024
Biotechnology stocks are experiencing somewhat of a revival this year. It has even lifted some cell and gene therapy company share prices, though certainly not all of them. The continued lack of robust revenue for approved cell and gene therapies is a reminder that being innovative doesn’t necessarily translate into profitability.
Innovation in terms of novel therapies that address unmet need is unquestionably a good thing. Take for example, Elevidys (delandistrogene moxeparvovec). Last June, the Food and Drug Administration approved this first gene therapy for Duchenne muscular dystrophy via the accelerated approval pathway. Although questions remain about the long-term efficacy of the treatment, for the 3,500 boys who are affected by this debilitating genetic disorder Elevidys is addressing a serious...
Today's Sponsors
Today's Sponsor